Multicenter phase I/II study on the anti-tumor activity, safety and pharmacology of IPH 2101, a human monoclonal anti KIR, combined with lenalidomide in patients with Multiple Myeloma experiencing a first relapse
ID Number 10-1670Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
Development of new treatments for diseases such as multiple myeloma (MM) is a focus of ongoing research. This research is being conducted on a research treatment called IPH2101, in combination with lenalidomide (Revlimid), a drug already approved by the Food and Drug Administration (FDA) to be used in combination with dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy. IPH2101 is an investigational drug not yet approved by the FDA.
Laboratory research already conducted regarding the combination of IPH2101 and lenalidomide suggest these agents together may kill multiple myeloma cells better than either agent alone, by enhancing “natural killer” or “NK” cell function (NK cells are the body’s own immune cells).
The purpose of this study is to determine:
• In the first part of the trial, the safety of increasing doses of IPH2101 combined with lenalidomide,
• In the second part of the trial, the ability of the combination research treatment of IPH2101 and lenalidomide to kill multiple myeloma cells.
Recruiting Patients: Yes